Azacitidine + Cedazuridine (oral)
Myelodysplastic Syndromes (inferred)
Phase 3 (inferred from ASH presentation)Active
Key Facts
Indication
Myelodysplastic Syndromes (inferred)
Phase
Phase 3 (inferred from ASH presentation)
Status
Active
Company
About Taiho Oncology
Taiho Oncology is a commercial-stage oncology company with a core focus on developing and marketing innovative small molecule cancer therapies. The company's lead commercial asset is LONSURF (trifluridine/tipiracil), an oral combination therapy approved for metastatic colorectal and gastric cancer. While the company has an active pipeline, as indicated by recent data presentations at major conferences, its public web presence shows significant technical issues, limiting detailed external analysis of its full pipeline, leadership, and partnerships. The company appears to be in a phase of leadership transition, having recently appointed a new President & CEO.
View full company profile